Researchers hope that identifying the genomic alterations specific to transformed small cell lung cancer (SCLC) can help ...

Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma ...

Topline pivotal Phase 3 firmonertinib data. ArriVent anticipates having topline firmonertinib monotherapy data from the event-driven global pivotal FURVENT Phase 3 (NCT05607550) study in 2025 and ...

CytomX Therapeutics, Inc.’s CTMX share price has surged by 11.93%, which has investors questioning if this is right time to sell.

Drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, occurring via secondary mutations or bypass pathways, is frequent among non-small-cell lung cancer patients.

Scientists at Harvard University are proposing a fundamental change in the way we consider psychedelics and their therapeutic ...

BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212, the company's first bispecific ADC. JS212 combines dual-targeting antibody technology with a cytotoxic ...

Dr. Suresh Ramalingam, executive director of Winship Cancer Institute of Emory University, received a standing ovation at the ...

The Congress of Neurological Surgeons (CNS) has updated its guidelines on using emerging therapies to treat metastatic brain ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

ORIC Pharmaceuticals, Inc.’s ORIC share price has dipped by 7.54%, which has investors questioning if this is right time to buy.

Janssen-Cilag International NV, a Johnson & Johnson company, has submitted an application to the European Medicines Agency ...